Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.46 |
| ▸ | RAB9A | P51151 | 5/20 | 0.46 |
| ▸ | SCN4A | P35499 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | TYR | P14679 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | MEN1 | O00255 | 4/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.38 |
| ▸ | GLP1R | P43220 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2706284 | 0.89 | NPC1 (0.50) | NPC1RAB9ASCN4ASMN1; SMN2TYR | |
| SCHEMBL12938128 | 0.89 | NPC1 (0.50) | NPC1RAB9ASCN4ASMN1; SMN2TYR | |
| SCHEMBL20049121 | 0.87 | NPC1 (0.40) | NPC1RAB9ASCN4ASMN1; SMN2TYR | |
| SCHEMBL20047578 | 0.84 | RAB9A (0.38) | NPC1RAB9ASCN4ASMN1; SMN2TYR | |
| SCHEMBL17460672 | 0.83 | NPC1 (0.46) | NPC1RAB9ASCN4ASMN1; SMN2TYR | |
| SCHEMBL18367038 | 0.83 | NQO2 (0.54) | NPC1RAB9ASCN4ASMN1; SMN2TYR | |
| SCHEMBL15279625 | 0.81 | NQO2 (0.56) | NPC1RAB9ASCN4ASMN1; SMN2TYR | |
| SCHEMBL12965808 | 0.79 | NQO2 (0.61) | NPC1RAB9ASCN4ASMN1; SMN2TYR | |
| SCHEMBL2756764 | 0.79 | NQO2 (0.61) | NPC1RAB9ASCN4ASMN1; SMN2TYR | |
| SCHEMBL18463005 | 0.78 | NPC1 (0.42) | NPC1RAB9ASCN4ASMN1; SMN2TYR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180169250-A1 | COVALENT LINKERS IN ANTIBODY-DRUG CONJUGATES AND METHODS OF MAKING AND USING THE SAME | REMEGEN CO., LTD. (CN) | 2018-06-21 | — | — | US | disclosed |
| US-20180085471-A1 | DRUG-CONJUGATES, CONJUGATION METHODS, AND USES THEREOF | SORRENTO THERAPEUTICS, INC. | 2018-03-29 | — | — | US | disclosed |
| US-20180055948-A1 | Covalent Linkers in Antibody-Drug Conjugates and Methods of Making and Using the Same | REMEGEN CO., LTD. (CN) | 2018-03-01 | — | — | US | disclosed |
| US-9884127-B2 | Drug-conjugates, conjugation methods, and uses thereof | CONCORTIS BIOSYSTEMS, CORP. (US) | 2018-02-06 | — | — | US | disclosed |
| US-9801951-B2 | Drug-conjugates, conjugation methods, and uses thereof | CONCORTIS BIOSYSTEMS, CORP. (US) | 2017-10-31 | — | — | US | disclosed |
| US-9801951-B2 | Drug-conjugates, conjugation methods, and uses thereof | CONCORTIS BIOSYSTEMS, CORP. (US) | 2017-10-31 | — | — | US | disclosed |
| US-20150141646-A1 | Drug-Conjugates, Conjugation Methods, and Uses Thereof | Concortis Biosystems, Corp., a wholly owned subsidary of Sorrento Therapeutics, Inc, (US) | 2015-05-21 | — | — | US | disclosed |
| US-20150105540-A1 | DRUG-CONJUGATES WITH A TARGETING MOLECULE AND TWO DIFFERENT DRUGS | SORRENTO THERAPEUTICS INC. (US) | 2015-04-16 | — | — | US | disclosed |
| US-20150105539-A1 | Drug-Conjugates, Conjugation Methods, and Uses Thereof | Concortis Biosystems, Corp., a wholly owned Subsidiary of Sorrento Therapeutics, Inc. (US) | 2015-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180085471-A1 | DRUG-CONJUGATES, CONJUGATION METHODS, AND USES THEREOF | ABCG2, UGT2B7, UGT1A9 | NPC1 330/4885RAB9A 764/4885SCN4A 4641/4885 |
| US-20180169250-A1 | COVALENT LINKERS IN ANTIBODY-DRUG CONJUGATES AND METHODS OF MAKING AND USING THE SAME | DHFR, FCGR1A, ADCY4 | NPC1 4243/4885RAB9A 2196/4885SCN4A 3803/4885 |
| US-20150141646-A1 | Drug-Conjugates, Conjugation Methods, and Uses Thereof | ABCG2, UGT2B7, UGT1A9 | NPC1 330/4885RAB9A 764/4885SCN4A 4641/4885 |
| US-20180055948-A1 | Covalent Linkers in Antibody-Drug Conjugates and Methods of Making and Using the Same | DHFR, FCGR1A, ADCY4 | NPC1 4243/4885RAB9A 2196/4885SCN4A 3803/4885 |
| US-20150105539-A1 | Drug-Conjugates, Conjugation Methods, and Uses Thereof | PAICS, CES2, DNPEP | NPC1 635/4885RAB9A 1067/4885SCN4A 4702/4885 |
| US-20150105540-A1 | DRUG-CONJUGATES WITH A TARGETING MOLECULE AND TWO DIFFERENT DRUGS | ERBB2, ABCG2, DYNLL2 | NPC1 2589/4885RAB9A 627/4885SCN4A 3771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.